CLL/SLL,   DLBCL,  PTCL,  FL,  MZL

ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Did you miss ASH 2018? The Lymphoma Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA and has developed a downloadable resource, which provides information on the practice changing abstracts across lymphoma and CLL.

Our selection of ASH 2018 abstracts include comments from The Lymphoma Hub Steering Committee members Stefano Luminari and Gilles Salles on ibrutinib combination therapies for the front-line treatment of CLL, and the role of the lenalidomide and rituximab combination in relapsed follicular lymphoma. Hear from the experts on the role of mutations that confer resistance to venetoclax and whether less is more when it comes to front line treatment in patients with DLBCL.

ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia

If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the Lymphoma Hub resource below:

Download Here
References
  1. #LBA-4: A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN cancer research group (E1912). 
    https://lymphomahub.com/medical-information/ash-2018-ibrutinib-plus-rituximabprovide-superior-outcomes-than-fcr-in-naive-cll-patients-results-from-the-ecog-acrinphase-iii-trial-e1912
  2. #LBA-7: Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. 
    https://lymphomahub.com/medical-information/novel-bcl2-mutation-leads-to-venetoclaxresistance-in-progressive-cll-patients
  3. #691: Ibrutinib + obinutuzumab versus chlorambucil + obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL): results from phase 3 iLLUMINATE.
    https://lymphomahub.com/medical-information/ash-2018-results-from-the-phase-iiiilluminate-trial-on-chemotherapy-free-first-line-treatment-for-cll-sll
  4. #781: Excellent outcome of young patients (18-60 years) with favorable-prognosis diffuse large B-Cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the Flyer trial of the Dshnhl/GLA.
    https://lymphomahub.com/medical-information/ash-2018-results-from-the-flyer-trial-on-the-efficacy-offour-r-chop-cycles-versus-six-in-young-nhl-patients
  5. #783: No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-Cell lymphoma patients: results from the international phase III GOYA study.
    https://lymphomahub.com/medical-information/ash-2018-results-from-the-phase-iii-goya-trial-r-chopversus-g-chop-for-first-line-dlbcl
  6. #997: The ECHELON-2 trial: results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas.
    https://lymphomahub.com/medical-information/brentuximab-vedotin-plus-chemotherapy-for-cd30-ptcl-results-from-the-phase-iii-echelon-2-trial
  7. #445: AUGMENT: A phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
    https://lymphomahub.com/medical-information/ash-2018-results-from-the-phase-iii-augmenttrial-lenalidome-plus-rituximab-for-r-r-fl-and-mzl
    https://lymphomahub.com/medical-information/nathan-fowler-ash-2018-long-term-updates-onlenalidomide-plus-rituximab-in-fl
Was this article informative? Thank you for your feedback!
100% of people found this article informative